Can you make notes on heart pathology micro pharma medicine and surgery

Asking for Preferences

Make overall notes from top to bottom from 1st year to final year topic all in one roof

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

COMPREHENSIVE HEART NOTES

From 1st Year to Final Year - Pathology | Microbiology | Pharmacology | Medicine | Surgery

PART 1: ANATOMY & HISTOLOGY (1st Year)

Cardiac Histology (Junqueira's Basic Histology)

Cardiac muscle: Involuntary striated muscle, branching fibers connected by intercalated discs
Intercalated discs contain:
- Fascia adherens - mechanical attachment (most of disc)
- Desmosomes - mechanical coupling
- Gap junctions (nexus) - electrical coupling, allows syncytium function
Myocyte features: single central nucleus, T-tubules at Z-line level, abundant mitochondria (30-35% cell volume)
Purkinje fibers (conduction system): large pale cells, rich in glycogen, sparse myofibrils

Coronary Anatomy (Bailey & Love; Gray's Anatomy)

Vessel	Territory Supplied
Left main stem (LMS)	Splits into LAD + Cx
LAD (Left Anterior Descending)	Anterior LV, anterior 2/3 septum, apex
Circumflex (Cx)	Lateral LV, SA node in 40%
Right Coronary Artery (RCA)	RV, SA node (60%), AV node (90%)

Right dominance (90%): RCA supplies posterior descending artery (PDA)
Left dominance (10%): Cx supplies PDA
LAD is the most frequently diseased and most often bypassed artery

PART 2: PHYSIOLOGY (1st Year)

Cardiac Action Potential

Phase 0 - Rapid depolarization (Na+ in)
Phase 1 - Early repolarization (K+ out, Cl- in)
Phase 2 - Plateau (Ca2+ in via L-type channels, K+ out)
Phase 3 - Rapid repolarization (K+ out)
Phase 4 - Resting potential (pacemaker cells show slow depolarization)

Starling's Law

Increased preload → increased stretch → increased stroke volume
Failing heart: operates on descending limb of Starling curve

Myocardial Infarction Physiology (Guyton & Hall; Ganong's)

Within seconds of occlusion: aerobic metabolism ceases → ATP drops → lactic acid accumulates
Reversible injury: up to ~20 minutes
Irreversible injury: >20-40 minutes → coagulative necrosis
Early death: 80-90% due to ventricular fibrillation (myocardial irritability), not mechanical failure
"Stunned myocardium" - post-reperfusion noncontractile but viable state

PART 3: PATHOLOGY - HEART (Robbins & Kumar; Robbins Cotran)

(This is the core exam section)

3A. Ischemic Heart Disease (IHD)

Atherosclerosis & Plaque

Underlying cause of IHD in >90% cases
Stable plaque: fibrous cap intact, luminal obstruction >70% needed to cause stable angina
Vulnerable plaque: thin cap, large lipid core, > rupture risk; most MIs arise from plaques with <70% stenosis
Plaque rupture → subendothelial collagen exposed → platelet adhesion → TXA2/ADP/serotonin → aggregation/vasospasm → thrombus → occlusion

Angina Pectoris

Type	Mechanism	Relief
Stable	Atherosclerotic stenosis + increased demand	Rest, nitrates
Unstable	Plaque disruption + non-occlusive thrombus	Aggressive treatment required
Prinzmetal/Variant	Coronary vasospasm (can occur in normal vessels)	Nitrates, Ca2+ channel blockers

Myocardial Infarction (MI)

Definition: "Presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of acute myocardial ischemia" (2018 ESC/ACC joint task force)

Epidemiology: 10% before age 40; 45% before age 65; men > women until menopause

Pathogenesis Sequence:

Plaque erosion/disruption
Platelet adhesion (collagen, vWF)
Platelet activation → TXA2, ADP, serotonin
Coagulation activation (tissue factor)
Complete thrombotic occlusion within minutes

Types by depth:

STEMI (Transmural): full thickness, occluded artery
NSTEMI (Subendocardial): innermost layer, partial/no occlusion

Morphologic Evolution - THE KEY TABLE:

Time	Gross	Microscopy
0-30 min	None	None (EM: myofibril relaxation, glycogen loss, mitochondrial swelling)
30 min-4 hrs	None	Wavy fiber change at borders; sarcolemmal disruption
4-12 hrs	Occasional dark mottling	Onset coagulation necrosis; edema; hemorrhage
12-24 hrs	Dark mottling	Coagulation necrosis; nuclear pyknosis; hypereosinophilic myocytes; marginal contraction band necrosis; early neutrophilic infiltrate
1-3 days	Yellow-tan center	Coagulation necrosis; loss of nuclei/striations; neutrophil infiltrate peaks
3-7 days	Hyperemic border; yellow-tan soft center	Neutrophil death; macrophage phagocytosis begins at border
7-10 days	Maximally yellow-tan, soft; depressed red-tan margins	Well-developed macrophage phagocytosis; early granulation tissue at margins
10-14 days	Red-gray depressed borders	Granulation tissue with new vessels + collagen deposition
2-8 weeks	Gray-white scar	Increased collagen, decreased cellularity
>2 months	Scar complete	Dense collagenous scar

Cardiac Biomarkers:

Troponin I/T: rise at 3-4 hrs, peak 12-24 hrs, elevated for 7-14 days (most specific/sensitive)
CK-MB: rise at 4-8 hrs, peak 12-24 hrs, normalizes at 48-72 hrs (useful for re-infarction)
Myoglobin: earliest (1-2 hrs), not specific
LDH: late marker, elevated up to 7 days

Complications of MI:

Complication	Timing	Notes
Arrhythmia	First 24-48 hrs	Most common cause of early death; VF most lethal
Cardiogenic shock	First days	>40% LV infarction; mortality 70-90%
LV free wall rupture	3-7 days	Massive hemopericardium → tamponade; "catastrophic"
Papillary muscle rupture	3-7 days	Acute MR; posterior papillary muscle more vulnerable (single blood supply)
Ventricular septal defect	3-7 days	New harsh pansystolic murmur
Pericarditis (epistenocardiac)	2-3 days	Friction rub; anterior chest pain
Mural thrombus	Days-weeks	Risk of systemic embolism
Ventricular aneurysm	Weeks-months	Anteroseptal scar; persistent ST elevation on ECG
Dressler syndrome	2-10 weeks	Autoimmune pericarditis; antibodies to myocardium

3B. Hypertensive Heart Disease

Left-sided: LV hypertrophy (concentric) - heart weight >500g, LV wall >2cm
Microscopy: increased myocyte diameter, "boxcar nuclei" (enlarged hyperchromatic), intercellular fibrosis
Clinical: initially asymptomatic → atrial fibrillation (from LA dilation) → diastolic dysfunction → CHF
Right-sided (Cor Pulmonale): RVH due to pulmonary hypertension (COPD most common cause in West)

3C. Valvular Heart Disease

Valve Lesion	Key Etiology	Murmur	Key Features
Mitral Stenosis	Rheumatic fever	Mid-diastolic (opening snap)	LA dilation, pulmonary hypertension, AF
Mitral Regurgitation	Ischemia, MVP, rheumatic, IE	Pansystolic at apex	Volume overload; LA + LV dilate
Aortic Stenosis	Calcific degeneration, congenital bicuspid aortic valve, rheumatic	Ejection systolic; radiates to carotids	Triad: angina, syncope, HF; gradient >40 = severe
Aortic Regurgitation	Rheumatic, IE, Marfan, syphilitic aortitis	Early diastolic (decrescendo)	Wide pulse pressure; collapsing/water-hammer pulse
MVP	Myxomatous degeneration	Midsystolic click + late systolic murmur	Young women; risk of MR, IE, arrhythmia

Rheumatic Heart Disease:

Group A Strep (GAS) pharyngitis → molecular mimicry → cross-reactive Ab against cardiac tissue
Aschoff bodies: pathognomonic; granulomatous lesions with Aschoff cells (modified macrophages with "owl eye" nuclei), surrounded by lymphocytes
Anitschkow cells: caterpillar cells (distinctive macrophages)
Valves affected in order: M > A > T > P (mitral most common)
Acute: pancarditis (endocarditis with MacCallum patches on LA, myocarditis, pericarditis)
Chronic: fibrosis + calcification → stenosis ("fish mouth" or "button hole" mitral stenosis)

Infective Endocarditis (IE):

Acute IE: S. aureus most common; virulent organism; normal valve; destructive vegetations
Subacute IE (SBE): S. viridans most common; low virulence; damaged/abnormal valve; smaller vegetations
Other organisms: Enterococcus, S. bovis (colon cancer!), HACEK group, Candida
IVDU: tricuspid valve most common; S. aureus
Vegetations: friable, irregular, on valve cusps; contain organisms + fibrin + platelets
Complications: valve destruction, septic emboli (kidney infarcts, splenic infarcts, brain abscess), immune complex glomerulonephritis
Duke Criteria: 2 major OR 1 major + 3 minor OR 5 minor = definite IE
- Major: positive blood cultures (×2), positive echo (vegetation/abscess/new regurgitation)
- Minor: fever >38°C, vascular phenomena (Janeway lesions), immunologic phenomena (Osler nodes, Roth spots, +RF), predisposing condition

3D. Cardiomyopathies

Type	Morphology	Cause	Key Features
Dilated (DCM)	LV + RV dilated; thin walls	Idiopathic (50%), alcohol, viral (Coxsackie B), peripartum, drugs (Doxorubicin)	Systolic failure; 4-chamber dilation; mural thrombi
Hypertrophic (HCM)	Asymmetric septal hypertrophy; banana-shaped LV	AD; sarcomere protein mutations (MYH7, MYBPC3)	Diastolic failure; LVOTO; sudden death in young athletes
Restrictive	Stiff, non-compliant walls; normal wall thickness	Amyloidosis, sarcoidosis, haemochromatosis, endomyocardial fibrosis	Diastolic failure; mimics constrictive pericarditis
Arrhythmogenic RV	Fibrofatty replacement of RV	PKP2 mutation (desmosome)	Right-sided HF; VT; sudden death in young

HCM Key Points:

Microscopically: myocyte disarray (whorled pattern), fibrosis
LVOTO due to systolic anterior motion (SAM) of mitral valve
Murmur: harsh ejection systolic; decreases with squatting/handgrip; increases with Valsalva/standing

3E. Pericardial Disease

Condition	Features
Fibrinous pericarditis	Bread-and-butter appearance; friction rub; post-MI, uraemia, RF
Serous pericarditis	Clear fluid; viral, SLE
Haemopericardium	Blood in pericardium; trauma, MI rupture, aortic dissection
Cardiac tamponade	Beck's triad: hypotension, muffled heart sounds, elevated JVP; pulsus paradoxus
Constrictive pericarditis	Obliterated pericardial space; TB most common worldwide; calcified pericardium on CXR

PART 4: MICROBIOLOGY (2nd Year)

Organisms in Heart Disease

Organism	Disease	Notes
Streptococcus pyogenes (GAS)	Rheumatic fever → RHD	M-protein cross-reactive with cardiac antigens
Streptococcus viridans	Subacute bacterial endocarditis	Most common SBE after dental procedures
S. aureus	Acute endocarditis; IVDU	Coagulase positive; produces toxins
S. bovis (S. gallolyticus)	SBE	Always screen for colorectal cancer
Enterococcus faecalis	Endocarditis	GI/GU procedures; resistant strains (VRE)
Coxsackievirus B	Viral myocarditis → DCM	B3, B4; most common viral cause
Treponema pallidum	Syphilitic aortitis	Obliterative endarteritis of vasa vasorum; aortic regurgitation
Trypanosoma cruzi	Chagas disease → myocarditis	South America; apical aneurysm; megaoesophagus
Diphtheria (C. diphtheriae)	Myocarditis (toxin-mediated)	Heart block; arrhythmia; exotoxin inhibits protein synthesis
Borrelia burgdorferi	Lyme carditis	AV block; tick bite
HACEK group	Subacute endocarditis	Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella

PART 5: PHARMACOLOGY (2nd-3rd Year)

5A. Antianginal Drugs

Drug Class	Examples	Mechanism	Side Effects
Nitrates	GTN, ISDN, ISMN	NO → ↑cGMP → vasodilation (venous >> arterial); ↓preload	Headache, tolerance, hypotension
Beta-blockers	Metoprolol, Atenolol, Carvedilol	Block β1 → ↓HR, ↓contractility, ↓O2 demand	Bradycardia, bronchospasm, fatigue
Calcium channel blockers	Amlodipine (DHP), Verapamil, Diltiazem	Block L-type Ca2+ channels	Amlodipine: oedema, flushing; Verapamil: constipation, AV block
Ivabradine	-	Blocks If "funny current" in SA node → ↓HR only	Not for ACS; use if BB intolerant
Ranolazine	-	Inhibits late Na+ current → ↓Ca2+ overload	QT prolongation

5B. Antihypertensive Drugs

Class	Drug	Mechanism	Indication/Notes
ACE Inhibitors	Ramipril, Enalapril, Lisinopril	Block ACE → ↓Angiotensin II → vasodilation + ↓aldosterone	Preferred in DM, post-MI, HFrEF, CKD; SE: dry cough, angioedema; CI: pregnancy
ARBs	Losartan, Valsartan, Candesartan	Block AT1 receptor	Use if ACEi cough; same cardiac benefit
Beta-blockers	Metoprolol, Bisoprolol, Carvedilol	↓HR, ↓renin	Post-MI, HF, angina, AF rate control
Dihydropyridine CCBs	Amlodipine, Nifedipine	Block Ca2+ in vascular smooth muscle → vasodilation	First-line; good in elderly, Afro-Caribbean
Non-DHP CCBs	Verapamil, Diltiazem	Block Ca2+ in heart + vessels	Rate control in AF; avoid with BB
Thiazide diuretics	Indapamide, HCTZ	Block NCC in DCT → ↓Na+/water	First-line alone or in combination; SE: hypoK+, hyperuricaemia, hyperglycaemia
Aldosterone antagonists	Spironolactone, Eplerenone	Block aldosterone receptor	Post-MI with HF; resistant hypertension

5C. Heart Failure Drugs

Class	Drug	Evidence/Benefit
ACE inhibitors	Ramipril (AIRE trial), Enalapril	Reduce mortality; first-line
Beta-blockers	Bisoprolol (CIBIS-II), Carvedilol, Metoprolol	Reduce mortality; start at low dose; uptitrate
MRA (Aldosterone antagonists)	Spironolactone, Eplerenone	Reduce mortality (RALES, EPHESUS trials)
SGLT2 inhibitors	Dapagliflozin, Empagliflozin	Reduce hospitalisation + mortality in HFrEF and HFpEF
ARNI	Sacubitril/Valsartan (LCZ696)	Superior to enalapril in PARADIGM-HF; combine ARB + neprilysin inhibitor
Loop diuretics	Furosemide	Symptom relief; ↓congestion; no mortality benefit
Digoxin	Digoxin	↑contractility; rate control in AF; narrow TI; toxicity: nausea, visual disturbance, arrhythmia
Ivabradine	Ivabradine	↓HR in sinus rhythm; add-on if HR >70 bpm

5D. Antiarrhythmic Drugs (Vaughan-Williams Classification)

Class	Examples	Channel Blocked	Use
Ia	Quinidine, Procainamide	Na+ (moderate); also K+	VT, AF (less used now)
Ib	Lignocaine (Lidocaine)	Na+ (fast off)	Acute VT/VF post-MI; IV only
Ic	Flecainide, Propafenone	Na+ (slow off)	AF/SVT; CI post-MI (CAST trial)
II	Metoprolol, Atenolol	β-adrenergic	AF rate control; SVT; post-MI
III	Amiodarone, Sotalol	K+	AF/VT/VF (Amiodarone - broadest spectrum); Sotalol also has β-block
IV	Verapamil, Diltiazem	Ca2+	SVT rate control; CI in AF+WPW
Other	Adenosine	A1 receptor → ↑K+	Acute termination of SVT; very short action
Other	Digoxin	Na/K ATPase	AF rate control

Amiodarone toxicities: Thyroid (hypo/hyper), pulmonary fibrosis, hepatotoxicity, corneal micro-deposits, photosensitivity, peripheral neuropathy, blue-grey skin discolouration.

5E. Anticoagulation in Cardiac Disease

Drug	Mechanism	Use in Cardiology
Heparin (UFH)	Activates ATIII → inhibits Xa + IIa	ACS (STEMI/NSTEMI), PE, DVT
LMWH (Enoxaparin)	Mainly anti-Xa	NSTEMI; more predictable than UFH
Warfarin	Inhibits Vit K reductase → ↓II, VII, IX, X	AF; prosthetic valves; DVT/PE
DOACs (Dabigatran)	Direct thrombin inhibitor	AF (non-valvular); DVT/PE
DOACs (Rivaroxaban, Apixaban)	Direct Xa inhibitors	AF; ACS (low dose); DVT/PE
Aspirin	Irreversible COX-1 inhibition → ↓TXA2	ACS; post-MI; CABG
Clopidogrel/Ticagrelor	P2Y12 inhibitor → ↓ADP-mediated platelet aggregation	ACS; post-PCI (dual antiplatelet)

PART 6: MEDICINE - CLINICAL CARDIOLOGY (3rd-4th Year)

6A. Acute Coronary Syndrome (ACS)

Classification:

STEMI: ST elevation + raised troponin → complete coronary occlusion
NSTEMI: No ST elevation + raised troponin → partial occlusion
Unstable Angina: No ST elevation + normal troponin

STEMI ECG Changes by Territory:

Territory	ECG leads	Artery
Anterior	V1-V4	LAD
Anterolateral	V4-V6, I, aVL	LAD/Cx
Inferior	II, III, aVF	RCA (90%)
Posterior	ST depression V1-V2; tall R waves	RCA/Cx
Lateral	I, aVL, V5-V6	Cx

STEMI Management (MONA + reperfusion):

Primary PCI within 90 min (preferred if available)
If PCI not available within 120 min: Thrombolysis (alteplase, streptokinase)
Antiplatelet: Aspirin 300mg + Ticagrelor/Clopidogrel (DAPT)
Anticoagulation: Heparin/LMWH/fondaparinux
MONA: Morphine, Oxygen (only if SpO2 <94%), Nitrates, Aspirin
Post-MI: ACEi + Beta-blocker + Statin (high intensity) + DAPT

NSTEMI/UA Management (GRACE score to stratify):

Conservative vs. early invasive strategy
DAPT + Anticoagulant (LMWH preferred)
Coronary angiography ± PCI within 24-72 hrs in high-risk

6B. Heart Failure

Classification:

HFrEF (EF <40%): systolic failure; dilated, weakly contracting LV
HFpEF (EF ≥50%): diastolic failure; stiff, non-compliant LV; common in elderly, hypertension, DM

NYHA Classification:

Class	Symptoms
I	No symptoms with ordinary activity
II	Slight limitation; symptoms with moderate exertion
III	Marked limitation; symptoms with minimal exertion
IV	Symptoms at rest

Clinical Features:

Left heart failure: orthopnoea, PND, pulmonary oedema, fine bilateral basal crackles, S3 gallop
Right heart failure: JVP raised, peripheral oedema, hepatomegaly, ascites
Congestive HF: both

Investigation:

BNP/NT-proBNP: excellent screening (elevated in HF)
Echocardiography: gold standard (EF, wall motion, valve function)
CXR: cardiomegaly (CTR >0.5), alveolar oedema, Kerley B lines, pleural effusion, upper lobe diversion
ECG: LVH, AF, LBBB (marker of poor prognosis)

Acute Pulmonary Oedema Treatment:

Position: sit upright
O2 (high-flow or CPAP/BiPAP)
IV Furosemide (40-80mg)
IV Nitrates (GTN infusion) - reduce preload
Morphine (reduces anxiety; vasodilation) - use cautiously
Inotropes (Dobutamine) if cardiogenic shock

Chronic HFrEF Treatment (Evidence-based):

ACE inhibitor (or ARNI if tolerated)
Beta-blocker (Bisoprolol/Carvedilol)
MRA (Spironolactone/Eplerenone)
SGLT2 inhibitor (Dapagliflozin/Empagliflozin)
Loop diuretic for symptoms (Furosemide)
Ivabradine if HR >70 on max BB
Device therapy: ICD (if EF <35%, NYHA II-III), CRT (if LBBB + EF <35%)

6C. Atrial Fibrillation (AF)

Mechanism: Multiple re-entrant circuits in atria (often from pulmonary vein foci)
Risk factors: Hypertension (most common), IHD, valvular disease, hyperthyroidism, alcohol ("holiday heart"), age

ECG: Irregularly irregular rhythm; absent P waves; fibrillatory baseline; variable ventricular rate

Classification: Paroxysmal (self-terminating <7d) / Persistent (>7d) / Long-standing persistent / Permanent

Complications: Stroke (most feared); heart failure; tachycardia-induced cardiomyopathy

CHA2DS2-VASc Score (for anticoagulation decision):

C: HF (1), H: HTN (1), A2: Age ≥75 (2), D: DM (1), S2: Stroke/TIA (2), V: Vascular disease (1), A: Age 65-74 (1), Sc: Sex (female +1)
Score ≥2 (male) or ≥3 (female) → anticoagulate with DOAC

Rate vs. Rhythm Control:

Rate control first (BB or non-DHP CCB)
Rhythm control: DC cardioversion; chemical (Flecainide, Amiodarone); Catheter ablation

6D. Valvular Heart Disease (Clinical)

Aortic Stenosis:

Triad: Angina → Syncope → (heart) Failure (ASF - survival worsens in this order)
Narrow pulse pressure; slow-rising carotid pulse; ejection systolic murmur
Severe: peak gradient >40 mmHg; valve area <1 cm2
Treatment: TAVI (transcatheter) for high surgical risk; AVR (surgical) for suitable patients

Mitral Stenosis:

Opening snap + mid-diastolic rumble with presystolic accentuation
Complications: AF, pulmonary hypertension, right heart failure, systemic emboli
Treatment: Balloon mitral valvuloplasty (if pliable, non-calcified); surgical commissurotomy/replacement

PART 7: SURGERY - CARDIAC SURGERY (Final Year)

7A. Coronary Artery Bypass Grafting (CABG)

(Bailey & Love; Sabiston Surgery)

Indications:

Left main stem (LMS) disease >50% stenosis
Triple vessel disease (especially with LV dysfunction)
Triple vessel disease + diabetes
Failed PCI / unsuitable anatomy for PCI
Angina refractory to medical therapy

Conduits:

Conduit	Patency	Notes
Internal Mammary Artery (IMA) - Left	90% at 10 years	Gold standard; preferred for LAD
Radial Artery	80-85% at 5 years	Second arterial conduit
Long Saphenous Vein (LSV)	50-60% at 10 years	Occlusion due to intimal hyperplasia; still widely used

Technique:

Most common: midline sternotomy + cardiopulmonary bypass (CPB)
CPB ("heart-lung machine"): oxygenates blood, keeps circulation going
Heart arrested with cardioplegia solution (high K+, cold)
Distal anastomoses first, then proximal to aorta
Off-pump CABG: beating heart surgery (OPCAB) - fewer CPB complications but technically harder

CPB Complications:

Coagulopathy, infection, air embolism
GI complications (ischaemia/pancreatitis)
Microembolisation (brain, eyes)
Postcardiotomy syndrome (Dressler-like)
Neurological dysfunction
Pulmonary injury

CABG vs. PCI (key randomised trials):

SYNTAX trial: CABG better for complex 3-vessel/LMS disease (high SYNTAX score)
FREEDOM trial: CABG superior to PCI in diabetics with multivessel disease
CABG remains gold standard for LMS, 3-vessel disease, DM, complex anatomy

7B. Valve Surgery

Procedure	Indication	Notes
Aortic Valve Replacement (AVR)	Severe AS (symptomatic) or severe AR with LV dysfunction	Mechanical (lifelong warfarin) or bioprosthetic (no anticoag, but re-op needed)
TAVI	Severe AS; high/inoperable surgical risk	Transfemoral approach commonest; dual antiplatelet post-procedure
Mitral Valve Repair	MR (preferred over replacement)	Better outcomes than replacement; preserve subvalvular apparatus
Mitral Valve Replacement	Severe MS not amenable to commissurotomy	Rheumatic disease
MitraClip	High-risk surgical patients with severe MR	Percutaneous leaflet approximation

7C. Cardiac Tamponade and Pericardiocentesis

Beck's triad: Hypotension + muffled heart sounds + elevated JVP
Pulsus paradoxus: >10 mmHg drop in SBP on inspiration
ECG: Electrical alternans (swinging heart in fluid)
Treatment: Pericardiocentesis (drain pericardial effusion); subxiphoid approach; echo-guided preferred

7D. Aortic Dissection

Type	Stanford	DeBakey	Treatment
Involves ascending aorta	Type A	I, II	Emergency surgery
Descending aorta only	Type B	III	Medical (beta-blockers) unless complications

Risk factors: Hypertension (most common), Marfan syndrome, bicuspid aortic valve, pregnancy
Presentation: Tearing/ripping chest pain radiating to the back; pulse deficit; neurological symptoms
Investigation: CT aortogram (gold standard)

7E. Cardiac Transplantation

Indications: End-stage HF (EF <20-25%), NYHA IV, refractory to all medical + device therapy
Contraindications: irreversible pulmonary hypertension, active infection, malignancy
Rejection: Hyperacute (ABO mismatch), Acute (T-cell mediated, most common), Chronic (vasculopathy)
Immunosuppression: Calcineurin inhibitors (Ciclosporin, Tacrolimus) + Mycophenolate + Prednisolone

PART 8: QUICK REVISION MNEMONICS

Topic	Mnemonic
Duke criteria for IE (major)	POSITIVE Blood cultures; ECHO (vegetations/abscess)
Aortic stenosis triad	ASF - Angina → Syncope → Failure
Jones criteria for RF (major)	JONES - J: Joints (migratory polyarthritis), O: cOrditiS, N: Nodules (subcutaneous), E: Erythema marginatum, S: Sydenham's chorea
HF drugs with mortality benefit	A-BES: ACEi/ARNI, Beta-blockers, Eplerenone/Spironolactone, SGLT2i
CABG indications	LMT-D: Left main, Multivessel + DM, Triple vessel, Disabled by angina
Antiarrhythmics by class	Some Block Potassium Channels Adequately: Sodium (I), Beta (II), Potassium (III), Calcium (IV), Adenosine/Digoxin (V)
MI complications 3-7 days (rupture risks)	"Dead muscle ruptures" - VSD, papillary muscle rupture, free wall rupture

PART 9: IMPORTANT INVESTIGATIONS SUMMARY

Investigation	What it tells you
12-lead ECG	MI territory, arrhythmia, LVH, PE (S1Q3T3), pericarditis (saddle-shape ST), tamponade (electrical alternans)
Troponin I/T	Myocyte injury; serial measurements at 0+3 or 0+6 hours
BNP/NT-proBNP	HF diagnosis and monitoring
Echocardiogram	EF, wall motion abnormalities, valve function, effusions, cardiomyopathy
Coronary angiogram	Gold standard for CAD - defines anatomy pre-CABG/PCI
CT aortogram	Aortic dissection
Cardiac MRI	Cardiomyopathy, viability, fibrosis (late gadolinium enhancement)
Holter monitor	Paroxysmal arrhythmia diagnosis
Exercise stress test	Ischaemia provocation; functional capacity in AS

Sources: Robbins & Kumar Basic Pathology; Robbins Cotran Pathologic Basis of Disease; Braunwald's Heart Disease; Bailey & Love's Short Practice of Surgery; Goldman-Cecil Medicine; Family Medicine Textbook (heart failure sections); Junqueira's Basic Histology; Guyton & Hall Medical Physiology; Ganong's Review of Medical Physiology

Can you make them in easiest pattern and concept to remember and clear my confusion and concept and make it in a pdf file for me to read

Reading File

Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "created"

Running Command

mkdir -p /tmp/workspace/heart-notes && echo "done"

This is a shared conversation. Sign in to Orris to start your own chat.